baber/WOPTO huggingface dataset:
Patent JP-2983631-B2 (JP)
IPC: G11B19/22
Filed: 1991-05-14
Granted: 1999-11-29
Abstract: PCT No. PCT/EP91/00891 Sec. 371 Date Dec. 3, 1992 Sec. 102(e) Date Dec. 3, 1992 PCT Filed May 14, 1991 PCT Pub. No. WO91/18391 PCT Pub. Date Nov. 28, 1991.Process for stopping a record-shaped, rotating information medium, for example, a CD. CD-players, for example, are provided with a loading and unloading mechanism for the information medium, the CD. However, before a CD can be automatically unloaded by the CD-player after reproduction or activation of a STOP-key, the rotation of the CD must be stopped in order to avoid damages of its sensitive surface. Because the moment of inertia and the diameter of records (CDs) are varied, and because a small mini-CD exists, it may occur that the CD is still rotating during the unloading process. To stop the record (CD) safely independently of its moment of inertia and its size, a first applied braking pulse (B1) causes the record (CD) to be braked to full stop and subsequently to be accelerated in the opposite direction. In the course of this braking and acceleration, the time T, which passes until the rotational speed of the record (CD) has reversed due to the first braking pulse (B1) from a preset value +N to a value -N, is measured. Moreover, when the rotational speed has reached the value -N, the polarity of the first braking pulse (B1) is reversed and a second braking pulse (B2) is applied and terminated after time T/2. As a result, the record (CD) will be safely and quickly braked from the rotational speed -N to a full stop. The process can be used, for example, for CD-players, video record players, DRAW-disc-players or magneto-optical sets.
Patent JP-3031933-B2 (JP)
IPC: C07H15/04
Filed: 1989-09-26
Granted: 2000-04-10
Abstract: The aliphatic primary alcohols are made to react with a glycose, in particular glucose, in the presence of an acid catalyst according to a process following given steps in such a manner that, in improved direct synthesis and after a subsequent necessary bleaching stage, particularly light-coloured and alkali-fast alkylglycosides are obtained. Said process can be carried out at laboratory level as well as on an industrial production scale.
Patent JP-3020275-B2 (JP)
IPC: B60H1/00
Filed: 1991-07-15
Granted: 2000-03-15
Abstract: PCT No. PCT/SE91/00493 Sec. 371 Date Mar. 26, 1993 Sec. 102(e) Date Mar. 26, 1993 PCT Filed Jul. 15, 1991 PCT Pub. No. WO92/01580 PCT Pub. Date Feb. 6, 1992.Device for selective climate control in vehicle cabins having a first air-vent duct (18) and a second air-vent duct (22) on respective sides or different zones in a vehicle cabin. The duct temperature on each side is measured and the duct adjustment is regulated by inner feedback control circuits. The cabin temperature (Tc1, Tc2 resp.) on both sides is measured, preferably at approximately head level, and fed to outer control circuits which determine the desired duct temperature as the deviation between the desired cabin temperatures (Tcs1, Tcs2 resp.) set by means of separate control knobs (38, 44) and the measured cabin temperatures (Tc1, Tc2 resp.). Desired duct temperature signals (Dts1, Dts2 resp.) are connected as input signals to respective inner control circuits.
Patent JP-3149190-B2 (JP)
IPC: C08L83/04
Filed: 1996-09-26
Granted: 2001-03-26
Abstract: PCT No. PCT/EP96/04210 Sec. 371 Date Mar. 23, 1998 Sec. 102(e) Date Mar. 23, 1998 PCT Filed Sep. 26, 1996 PCT Pub. No. WO97/12939 PCT Pub. Date Apr. 10, 1997The invention relates to organopolysiloxane compounds which can be stored subject to the exclusion of moisture, can be cross-linked by cleaving of alcohols to form elastomers when moisture gains access at room temperature and are based on (A) polydiorganosiloxanes with organyloxy groups, optionally (B) organyloxy functional cross-linkers with at least three organyloxy groups, and optionally (C) condensation catalysts, characterised in that they contain at least one (D) compound selected from the compounds (Da) to (Df) given in claim 1.
Patent JP-2701092-B2 (JP)
IPC: C12Q1/68
Filed: 1993-04-02
Granted: 1998-01-21
Abstract: Method and composition for detecting one or more selected polynucleotide regions in a target polynucleotide. In one embodiment of the invention, a plurality of different-sequence probe pairs are added to a target polynucleotide, where each probe pair includes two polynucleotide probe elements which are complementary in sequence to adjacent portions of a selected one of the target sequences in the target polynucleotide. In each probe pair, one of the probe elements contains a non-polynucleotide polymer chain which imparts a distinctive mobility to the associated probe pair, when the elements in the pair are ligated. The other element in the pair contains a detectable reporter label. After the probe pairs have been allowed to hybridize with the target polynucleotide, the hybridized polynucleotides are treated under conditions effective to ligate the end subunits of target-bound probe elements when their end subunits are base-paired with adjacent target bases. The ligated probe pairs are then released from the target polynucleotide and separated electrophoretically in a sieving matrix, or chromatographically.
Patent JP-3271991-B2 (JP)
IPC: A61P37/00
Filed: 1998-11-06
Granted: 2002-04-08
Abstract: This invention provides a compound having both IL-4 production inhibitory activity and PDE (IV) inhibitory activity, represented by formula (I): <CHEM> Äwherein A represents a triazole group; R1 and R2 may be the same or different from each other and each represents an aliphatic hydrocarbon radical which may have an alicyclic or aromatic hydrocarbon radical or an alicyclic hydrocarbon radical; R3 represents hydrogen atom or a substituent group; and R4 represents a hydrogen atom or a protective group of the nitrogen atomÜ, and a pharmaceutical composition, a therapeutic or preventive agent for acute and chronic inflammatory diseases and an anti-allergic or anti-inflammatory agent, each of which comprising an effective amount of the compound and a pharmacological carrier. It also provides use of the compound of formula (I) for the production of the aforementioned pharmaceutical composition, therapeutic or preventive agent for acute and chronic inflammatory diseases and anti-allergic or anti-inflammatory agent, and a method for treating and/or preventing acute and chronic inflammatory diseases.
Patent JP-3587855-B2 (JP)
IPC: E04B1/61
Filed: 1996-02-29
Granted: 2004-11-10
Abstract: Flooring panel or wall panel and a use thereof in a wet room. The panel is provided with a locking means in the form of groove and tongue forming a tongue/groove joint for assembling of the panels. The groove and the tongue are preferably made of water tight material and formed with a snap-together joint.
Patent JP-3091496-B2 (JP)
IPC: C09D7/62
Filed: 1997-02-12
Granted: 2000-09-25
Abstract: Anatase titanium dioxide particles no larger than 100 nm and coated with a layer of a metal oxide, hydroxide or oxohydroxide, said particles having a BET specific surface area of at least 70 m<2>/g and a density of around 2.2. A method for preparing said particles, and the use thereof as an anti-UV agent, in particular for preparing formulations for cosmetics, varnishes, paints and plastics, are also disclosed.
Patent JP-4126089-B2 (JP)
IPC: A61B17/00
Filed: 1998-04-23
Granted: 2008-07-30
Abstract: A device for implanting a bone plate is disclosed. The device includes an endoscope attachment element having a body member sized to receive at least a portion of an endoscope and a bone plate holder having one end sized to receive at least a portion of a bone plate. The bone plate holder is operatively associated with the body member of the attachment element to move the bone plate holder between a first retracted position and a second implanting position. In preferred embodiments, the attachment element includes a guide track for providing sliding movement of the holder and the track has a plurality of catches for grasping a locking button on the holder to retain the holder in the implanting position. The device preferably includes a locking member having a connecting tube operatively associated with the bone plate to guide and enable fastening operations through an aperture in the body member of the attachment element so that the bone plate can be secured to bone.
Patent MD-2300-B2 (MD)
Title: Continuous vibratory mixer
Inventor: ANDRIEVSCHI SERGHEI
IPC: B28C5/04
Filed: 2001-11-22
Abstract: The invention relates to the mechanical engineering and may be used for preparation of dry, semidry, mortar and concrete mixes. The mixer contains a cylindrical body, which is carried by shock-mounting supports, a vibration exciter, charging ports for the mix components and for the liquid and a mix discharging port. In the center of the body there is placed a shaft with mixing members, its ends being carried by bearings, installed in antivibrating collars. The mixing members are made in the form of bars and placed onto the shaft surface in a helical line. The distance between the bars ends and the body inner surface is greater than the maximal dimension of the mixing particles.The result of the invention consists in increasing the action volumetric zone of the mixing members upon the material that leads to the intensification of the process and to the improvement of the mixing quality.Claims: 1Fig.: 2
Patent ES-2364793-B2 (ES)
Title: Fijación de la ruta de flujos portadores de ip en una red de próxima generación.
Inventor: CASEY LIAM
IPC: H04L12/12
Filed: 2007-11-15
Granted: 2012-04-20
Abstract: Métodos y sistemas para extender la arquitectura de IMS/SIP de la NGN con el fin de proporcionar servicio de QoS a flujos portadores genéricos. Más particularmente, se proporciona un método para establecer un camino portador de extremo a extremo de una sesión de comunicación en una red de comunicación de múltiples dominios en la que se utiliza un protocolo de señalización fuera de banda para establecer sesiones de comunicaciones. El método comprende recibir un mensaje de señalización fuera de banda que incluye información representativa de al menos un punto de extremo opuesto de un primer segmento portador del camino de extremo a extremo. La información se utiliza para definir una relación de correspondencia de conexión cruzada a través de un nodo de la red entre respectivos puntos de extremo locales del primer segmento portador y del segundo segmento portador alojados por el nodo. Se inserta entonces información representativa de la relación de correspondencia de conexión cruzada en el mensaje de señalización fuera de banda, y se remite el mensaje de señalización fuera de banda.
Patent ES-2631881-B2 (ES)
Title: Dispositivo de anclaje rígido antivibratorio para la construcción
Inventor: SALCEDO HERNÁNDEZ JOSÉ CARLOS
IPC: E02D27/50
Filed: 2016-03-03
Granted: 2018-05-23
Abstract: Dispositivo de anclaje rígido antivibratorio para la construcción.#La presente invención consiste en un dispositivo formado por una placa de acero y una pluralidad de barras de anclaje de acero para dejar metidas en una base de hormigón durante su estado fresco; caracterizado porque dispone en todas las superficies que quedan en contacto con el hormigón, de un material aislante antivibratorio, de manera tal que no existe contacto directo entre el acero del dispositivo y el hormigón de la base, sino que existe contacto indirecto por medio de este material antivibratorio que sirve para absorber las vibraciones y que a la vez transmite por presión las acciones y reacciones de momento, fuerza vertical, fuerza horizontal y torsión.#La invención puede ser usada tanto para el apoyo de máquinas e instalaciones, para mejorar las prestaciones del simple apoyo aislante convencional o silentblock del estado de la técnica; como para nudos de estructuras de construcciones.#Se determinan por cálculo el espesor y las características aislantes del material antivibratorio empleado, en cada posición de la placa, barras de anclaje o perfiles; en función de la transmisión de tensiones que requiere el nudo.
Patent AU-2001258587-B2 (AU)
Title: Fastening apparatus and method
Inventor: GETHINGS MICHAEL SHAUN BRIAN
IPC: B21B31/08
Filed: 2001-05-22
Granted: 2005-01-06
Abstract: A fastening apparatus adapted for use with an annular first article (76) and an second article (75) which locates within the first article (76) such that a first end of the second article (75) projects through and beyond a first end of the first article (76) and a second end of the first article (76) is located relative to the second article (75). The apparatus comprises a housing (50), a piston (58) movably situated within the housing (50) to allow at least one locating portion (62) of the piston (58) to be retained within the housing (50) or to project through a corresponding opening (61) in the housing (50), pressure means (69) provided within the housing (50) to act on the piston (58), and at least one fastening member (71) attached to the housing (50). <IMAGE>
Patent AU-2002245263-B2 (AU)
Title: Assessment of tooth structure using laser based ultrasonics
Inventor: BALDWIN KEVIN C
IPC: A61B5/00
Filed: 2002-01-10
Granted: 2005-11-03
Abstract: A means of assessing the internal structure of teeth based upon use of high frequency, highly localized ultrasound (acoustic waves) generated by a short laser pulse is presented. In contrast to traditional contact transducer methods, laser-generated ultrasound is non-contact and non-destructive in nature and requires no special tooth surface preparation. Optical interferometric detection of ultrasound provides a complementary non-destructive, non-contact means for obtaining data with a very small detection footprint. The combination of laser-generated ultrasound and optical interferometric detection allows for in-vivo diagnostics of tooth health that is sensitive to the enamel/dentin, dentin/pulp, and dentin/cementum interfaces as well as a region of dead tracts in the dentin within a tooth.
Patent AU-2002308986-B2 (AU)
Title: Process for preparation of a quinolinecarbaldehyde
Inventor: SHIMIZU TAKANORI
IPC: C07D215/14
Filed: 2002-05-15
Granted: 2007-05-31
Abstract: A process for producing 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-carbaldehyde important as intermediate for the synthesis of pharmaceuticals, efficiently from an unnecessary antipode, is provided. <??>A process for producing 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-carbaldehyde represented by the formula (III): <CHEM> which comprises treating a compound represented by the formula (I) or (II): <CHEM> (wherein A is -CHOH or -C(O)-, and R is a hydrogen atom, a C1-4 alkyl group which may be branched, a phenyl group, an alkali metal ion or an alkaline earth metal ion) with ozone, followed by reduction with an inorganic sulfur compound or by hydrogenation for reduction decomposition.
Patent AU-2002359452-B2 (AU)
Title: Method of applying non-linear dynamics to control a gas-phase polyethylene reactor operability
Inventor: FINNEY CHARLES
IPC: C08F10/02
Filed: 2002-11-22
Granted: 2005-11-03
Abstract: The present invention describes a method for determining reactor continuity of a polymerization reactor by non-linear dynamics. Specifically, the invention relates to a method of analyzing system variables to indicate gas phase reactor continuity in real-time and controlling the reactor continuity to maintain operability.
Patent AU-2002365016-B2 (AU)
Title: Benzimidazole derivatives and their use as GnRH antagonists
Inventor: BRAULT VALERIE
IPC: C07D521/00
Filed: 2002-12-20
Granted: 2008-11-20
Abstract: 2-(Alkylamino or alkylthio)-5-(aminocarbonyl or aminomethyl)-benzimidazole derivatives (I) are new.  2-(Alkylamino or alkylthio)-5-(aminocarbonyl or aminomethyl)-benzimidazole derivatives of formula (I), in racemic or enantiomer form or any combination of these forms, and their salts are new.  A  = CH2 or CO;  Y  = S or NH;  R1, R2  = H, 1-8C alkyl, 5-9C bicycloalkyl (optionally substituted (os) by one or more T) or -(CH2)a-X; or  NR1R2  = heterocycloalkyl, heterobicycloalkyl or a spiro or fused piperidine group of formula (i), (ii), (iii) or (iv) (all os by one or more of -(CH2)c-X''-Y'', oxo, hydroxy, halo, nitro or cyano);  T  = 1-6C alkyl;  X  = NH2, NHT, NT2, adamantyl, arylcarbonyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, indanyl or tetralinyl or 3-7C cycloalkyl, heterocycloalkyl, aryl or heteroaryl (os by one or more of -(CH2)b-X'-Y', halo, oxo, NO2, CN, NH2, NHT, NT2, OH or N3);  X'  = O, S, C(O), C(O)O, NHC(O), NHSO2 or direct bond;  Y'  = T (os by one or more halo) or heteroaryl, aryl or heterocycloalkyl (all os by one or more of T, OT, halo, NO2, CN, NH2, CF3, OCF3, OH, N3, NHT or NT2);  X''  = O, C(O), C(O)O or direct bond;  Y''  = T, NH2, NHT, NT2, 3-7C cycloalkyl, heterocycloalkyl or aralkyl; aryl or heteroaryl (both os by one or more of T, OT, COT, halo, OH, NO2, CN, CF3, OCF3, NH2, NHT or NT2); or 1,4-benzodioxanyl, 1,3-benzodioxolyl or benzimidazol-2-on-1-yl;  a  = 0-6;  b  = 0-2;  c  = 0-4;  R3  = -(CH2)c-W3-(CH)2d-Z3;  W3  = direct bond, CH(OH) or C(O);  Z3  = T, adamantyl, aryl, heteroaryl, 1,4-benzodioxanyl, 1,3-benzodioxolyl or anthraquinonyl (where all aryl groups are os by one or more of -(CH2)e-V3-Y3, halo, NO2, CN, N3 or OH;  V3  = O, S, C(O), C(O)O, SO2 or direct bond;  Y3  = T, os by one or more halo, NH2, NHT, NT2, CH2COPh, heterocycloalkyl or aryl;  c, d, e  = 0-4;  R4  = -(CH2)f-R''4;  R''4  = heterocycloalkyl containing at least one N (os by T or aralkyl); heteroaryl containing at least one N (os by T); or -NW4W'4;  W4  = H, T or cycloalkyl;  W'4  = -(CH2)g-Q4-Z4;  Q4  = -CH2CH(OH)-(CH2)h-(O)i-(CH2)j or -C(O)O;  Z4  = H, 1-8C alkyl (os by one or more of OT, ST, SST and OH), 2-6C alkenyl, 2-6C alkynyl, 3-7C cycloalkyl (os by one or more alkyl, COOT or -T-OH), cyclohexenyl, adamantyl, heteroaryl, aryl (os by one or more of -(CH2)k-V4-Y4, OH, NO2, halo or CN), 1,4-benzodioxanyl or 1,3-benzodioxolyl;  V4  = O, S, NHC(O) or direct bond;  Y4  = T (os by NT2 or one or more halo), NH2, NHT, NT2, aralkyl or heterocycloalkyl;  f, g  = 0-4;  h, i, j  = 0 or 1; and k  = 0-4.
Patent AU-2003216748-B2 (AU)
Title: Novel anti-IGF-IR antibodies and uses thereof
Inventor: GOETSCH LILIANE
IPC: C12N1/19
Filed: 2003-01-20
Granted: 2009-07-16
Abstract: An isolated antibody (Ab), and its functional fragments, that bind to human insulin-like growth factor-1 receptor (IGF-1R) and optionally: (i) inhibit natural binding of insulin-like growth factors (IGF)-1 and/or -2; and/or (ii) inhibit specifically tyrosine kinase activity of IGF-1R. An isolated antibody (Ab), and its functional fragments, that bind to human insulin-like growth factor-1 receptor (IGF-1R) and optionally inhibit natural binding of insulin-like growth factors (IGF)-1 and/or -2 and/or inhibit specifically tyrosine kinase activity of IGF-1R, is new. Ab comprises: (a) a light chain containing at least one complementarity-determining region (CDR) of one of 3 fully defined sequences comprising 16, 7 or 9 amino acids as given in the specification; or (b) a heavy chain containing at least one of the CDRs of one of 3 fully defined sequences comprising 6, 16 or 8 amino acids as given in the specification or sequences with 80% identity after optimal alignment. Independent claims are also included for the following: (1) murine hybridomas that secrete Ab; (2) an isolated nucleic acid (I) that: (a) is RNA or DNA and encodes Ab or its fragments; (b) is the complement of (a); or (c) has at least 18 nucleotides that can hybridize under stringent conditions with any of six sequences fully defined in the specification that encode the specified CDR, or with sequences having 80% identity after optimal alignment; (3) a vector containing (I); (4) a host cell containing the vector of (3); (5) a non-human transgenic animal containing at least one cell transfected with the vector of (3); (6) producing Ab or its fragments; (7) in vitro diagnosis of diseases induced by over- or under-expression of IGF-1R and or EGFR (epidermal growth factor receptor) by reaction with optionally labeled Ab; and (8) kit for performing method (7). ACTIVITY : Cytostatic; Antipsoriatic. The murine antibody 7C10, specific for IGF-1R, was tested (at 250 Microgram twice a week, intraperitoneally) against MCF-7 breast cancer cells, implanted in nude mice. After 37 days, the mean tumor volume was about 150 mm 3>; compared to about 800 mm 3> for controls and 300 mm 3> for animals treated with 10 Microgram tamoxifen. MECHANISM OF ACTION : Inhibition of signal transduction pathways mediated by IGF-1R, optionally also by epidermal growth factor (EGF) receptor, thus inhibiting growth and/or proliferation of tumor cells, especially where dependent on IGF, EGF, estrogens and/or HER2/neu.
Patent AU-2003237557-B2 (AU)
Title: A weight management system for obese animals
Inventor: WILSON MICHAEL J
IPC: A23K20/195
Filed: 2003-01-22
Granted: 2007-07-26
Abstract: A diet system for promoting comprehensive weight management in companion animals. The diet system includes a stage I pet food product for promoting weight loss and building lean body mass and a stage II pet food product for maintaining the weight loss and the lean body mass.
Patent AU-2003265858-B2 (AU)
Title: Infusion therapy flow rate adjustment system and method
Inventor: PAUL ERIC S
IPC: G06F19/00
Filed: 2003-04-28
Granted: 2008-12-04
Abstract: A system and method for verifying that the right medication is efficiently provided to the right patient, in the right dose, at the right time, and via the right route. The invention also relates to efficiently coordinating infusion therapy with patient care system billing and inventory subsystems.
Patent AU-2004216693-B2 (AU)
Title: Conditional access system and method
Inventor: ROSEMAN STUART
IPC: H04L9/00
Filed: 2004-03-04
Granted: 2009-11-19
Abstract: The present invention relates to methods of and systems for providing conditional access to electronic content. Electronic content is provided to a user along with authorization information. The electronic content may be transmitted to the user, and the user may use the authorization information to access the electronic content. An authorization code may be provided to the user such that the user may be granted access to the content based on a comparison of the provided authorization code and a second authorization code transmitted with the electronic content, and transmission of the second authorization code may be controlled by a content provider to control access by the user.
Patent AU-2004253242-B2 (AU)
Title: Formulations for the treatment of arhritis conditions
Inventor: BOMBARDELLI EZIO
IPC: A61K36/324
Filed: 2004-06-01
Granted: 2010-02-18
Abstract: The present invention relates to formulations comprising combinations of analgesic/anti-inflammatory, immunomodulating and cartilage-reconstructing agents in particular comprising saligenig, boswellic acid, procyanidins, N-acety-glucosamine and either glucoronic acid or glucoronolactone, for the treatment of rheumatoid arthritis and, more generally, of arthritis conditions.
Patent AU-2004284079-B2 (AU)
Title: Aluminum conductor composite core reinforced cable and method of manufacture
Inventor: GEORGE KORZENIOWSKI
IPC: D04H3/08
Filed: 2004-10-22
Granted: 2011-08-18
Abstract: This invention relates to an aluminum conductor composite core reinforced cable (ACCC) and method of manufacture. An ACCC cable (300) has a composite core surrounded by an outer film (305) and at least one layer of aluminum conductor (306). The composite core (303) comprises a plurality of fibers from at least one fiber type in one or more matrix materials. According to the invention, unique processing techniques such a B-Staging and / or film-coating techniques can be used to increase production rates from a few feet per minute to sixty or more feet per minute.